Eli Lilly

CrossBridge Bio plans to submit an Investigational New Drug (IND) application for CBB-120, positioning the candidate for clinical development.

When combined with a reduced-calorie diet and regular physical activity, Foundayo helps patients shed excess weight and maintain their progress.

Beyond the initial payment, Centessa shareholders are set to receive an extra USD9 per share in contingent value rights (CVR), which could increase the total deal value by USD1.5 billion.

This latest commitment builds on a previous 7 billion yen (USD44 million) investment between 2022 and 2025, which funded automated device-sorting machines, enhancements to the quality testing lab, a new factory building, and an additional packaging line.

The company plans to execute this investment through two primary channels: expanding existing facilities and forging partnerships with local manufacturers.

The acquisition gives Lilly access to Orna’s innovative platform, which combines circular RNA (circRNA) with lipid nanoparticle-based therapies.

This new facility marks Lilly’s fourth major U.S. manufacturing project in recent years and adds to its broader domestic expansion strategy.

Eli Lilly will obtain exclusive global rights to advance these programmed recombinases through preclinical studies, clinical development, and eventual commercialization.

The companies unveiled their partnership at the 2026 J.P. Morgan Healthcare Conference, which took place from January 12 to 15 in San Francisco.